Bayesian approaches to benefit-risk assessment for diagnostic tests

被引:0
|
作者
Bai, Tianyu [1 ]
Lan, Huang [1 ]
Tiwari, Ram [1 ]
机构
[1] US FDA, Ctr Device & Radiol Hlth, Silver Spring, MD USA
关键词
Diagnostic tests; benefit-risk evaluation; Monte-Carlo simulations; MCMC; power prior; binary outcomes;
D O I
10.1080/10543406.2021.1931272
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Benefit-risk assessment plays an important role in the evaluation of medical devices. Unlike the therapeutic devices, the diagnostic tests usually affect patient life indirectly since subsequent therapeutic treatment interventions (such as proper treatment in time, further examination or test, no action, etc.) will depend on correct diagnosis and monitoring of the disease status. A benefit-risk score using statistical models by integrating the information from benefit (true positive and true negative) and risk (false positive and false negative) for diagnostic tests with binary outcomes (i.e., positive and negative) will help evaluation of the utility and the uncertainty of a particular diagnostic device. In this paper, we develop two types of Bayesian models with conjugate priors for constructing the benefit-risk (BR) measures with corresponding credible intervals, one based on a Multinomial model with Dirichlet prior, and the other based on independent Binomial models with independent Beta priors. We then propose a Bayesian power prior model to incorporate the historical data or the real-world data (RWD). Both the fixed and random power prior parameters are considered for Bayesian borrowing. We evaluate the performance of the methods by simulations and illustrate their implementation using a real example.
引用
收藏
页码:541 / 558
页数:18
相关论文
共 50 条
  • [1] Benefit-risk assessment for binary diagnostic tests
    Bai, Tianyu
    Huang, Lan
    Li, Meijuan
    Tiwari, Ram
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2019, 29 (05) : 760 - 775
  • [2] Comparing diagnostic tests on benefit-risk
    Pennello, Gene
    Pantoja-Galicia, Norberto
    Evans, Scott
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2016, 26 (06) : 1083 - 1097
  • [3] A Bayesian Approach for Benefit-Risk Assessment
    Zhao, Yueqin
    Zalkikar, Jyoti
    Tiwari, Ram C.
    LaVange, Lisa M.
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2014, 6 (04): : 326 - 337
  • [4] Bayesian Approach to Personalized Benefit-Risk Assessment
    Cui, Shiqi
    Zhao, Yueqin
    Tiwari, Ram C.
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2016, 8 (03): : 316 - 324
  • [5] SEMIPARAMETRIC BAYESIAN MARKOV ANALYSIS OF PERSONALIZED BENEFIT-RISK ASSESSMENT
    Yan, Dongyan
    Guha, Subharup
    Ahn, Chul
    Tiwari, Ram
    [J]. ANNALS OF APPLIED STATISTICS, 2020, 14 (02): : 768 - 788
  • [6] A Systematic Review of Methodological Approaches for Benefit-Risk Assessment of Vaccines
    Arlegui, Hugo
    Bollaerts, Kaatje
    Salvo, Francesco
    Bauchau, Vincent
    Nachbaur, Gaelle
    Begaud, Bernard
    Praet, Nicolas
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 624 - 625
  • [7] Implementing Benefit-Risk Assessment for the Periodic Benefit-Risk Evaluation Report
    Warner, Margaret R.
    Wolka, Anne M.
    Noel, Rebecca A.
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2016, 50 (03) : 342 - 346
  • [8] Implementing Benefit-Risk Assessment for the Periodic Benefit-Risk Evaluation Report
    Margaret R. Warner
    Anne M. Wolka
    Rebecca A. Noel
    [J]. Therapeutic Innovation & Regulatory Science, 2016, 50 : 342 - 346
  • [9] A Bayesian approach to probabilistic sensitivity analysis in structured benefit-risk assessment
    Waddingham, Ed
    Mt-Isa, Shahrul
    Nixon, Richard
    Ashby, Deborah
    [J]. BIOMETRICAL JOURNAL, 2016, 58 (01) : 28 - 42
  • [10] The Case for a Bayesian Approach to Benefit-Risk Assessment:: Overview and Future Directions
    Costa, Maria J.
    He, Weili
    Jemiai, Yannis
    Zhao, Yueqin
    Di Casoli, Carl
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2017, 51 (05) : 568 - 574